Phase 1 first-in-human (FIH) study of nesvacumab (REGN910) a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb): Results from hepatocellular carcinoma (HCC) cohort

Authors :: Pamela Trail
Anthony W. Tolcher
Rebecca Arcos
Sharvina Ziyeh
Kyriakos P. Papadopoulos
Robin Kate Kelley
Katherine Van Loon
Lillian L. Siu
Israel Lowy
Muralidhar Beeram
Philippe L. Bedard
Albiruni Ryan Abdul Razak
Carrie Brownstein
Bo Gao
Lieve Adriaens
Source :: Journal of Clinical Oncology. 32:2540-2540
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: 2540 Background: Nesvacumab (N) is an Ang2 selective, human MAb that potently blocks signaling through the Tie2 receptor, inhibiting tumor angiogenesis and growth. In mouse xenograft models of huma...

Subjects :: Nesvacumab
Tumor angiogenesis
Cancer Research
business.industry
medicine.drug_class
Angiopoietin 2
First in human
Monoclonal antibody
medicine.disease
Oncology
Mouse xenograft
Hepatocellular carcinoma
Immunology
Cancer research
Medicine
Tie2 Receptor
business

Tools